Interestingly,platinum drugs are often paired with pemetrexed, or combined with ALK (anaplastic lymphoma kinase) inhibitors suchas crizotinib and ceritinib for the treatment of ALK-rearranged NSCLC. ALK is a receptor tyrosine kinase involved incellular signaling pathways that promote proliferation and survival;its dysregulation contributes to oncogenesis. ALK inhibitors block the kinase activity of the protein, therebyinhibiting downstream signaling cascades. Here, ALK is linked to non-small cell lung carcinoma.